Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 35 Show results per page	View Search Criteria \| Help With Results

Last Modified: 2/12/2007 First Published: 2/3/2006


1.		Phase III Randomized Study of Vorinostat (SAHA) in Patients With Progressive or Relapsed Advanced Malignant Pleural Mesothelioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				NCI-06-C-0040 MERCK-014-01, NCI-P6690, NCT00265577, UCLA-0506053-01, MERCK-014-00

Last Modified: 10/25/2007 First Published: 11/18/2005


2.		Phase I/II Study of Vorinostat and Trastuzumab (Herceptin®) in Patients With Metastatic or Local Chest Wall Recurrent Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Temporarily closed				18 and over				NCI				ECOG-E1104 E1104, NCT00258349

Last Modified: 8/29/2008 First Published: 8/18/2006


3.		Phase I/II Study of Vorinostat (SAHA) in Combination With Paclitaxel and Bevacizumab in Patients With Metastatic and/or Locally Recurrent Inoperable Chest Wall Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				AECM-0605291 06-05-291, NCI-7703, 7703, NCT00368875


4.		An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				2004_029 MK0683-013, NCT00097929

Last Modified: 7/30/2007 First Published: 6/25/2005


5.		Phase II Study of Suberoylanilide Hydroxamic Acid in Patients With Progressive, Persistent, or Recurrent Stage IB-IV Cutaneous T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0412112-01 MERCK-CL-01-0303 (2), NCT00091559, MERCK-001-02

Last Modified: 12/2/2008 First Published: 7/15/2005


6.		Phase II Study of Vorinostat (SAHA) in Patients With Metastatic or Unresectable Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				PMH-PHL-040 NCI-6916, 6916, NCT00121225

Last Modified: 2/8/2007 First Published: 7/22/2005


7.		Phase II Study of Suberoylanilide Hydroxamic Acid in Patients With Relapsed Diffuse Large B-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0411065-01 MERCK-013-00, NCT00124631

Last Modified: 1/13/2009 First Published: 8/12/2005


8.		Phase II Study of Suberoylanilide Hydroxamic Acid as Salvage Therapy in Patients With Progressive Stage IV Adenocarcinoma of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				CCC-PHII-62 6918, NCI-6918, NCI-P6918, NCT00132002

Last Modified: 8/2/2007 First Published: 8/12/2005


9.		Phase II Study of Vorinostat (SAHA) in Patients With Relapsed or Primary Refractory Advanced Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				SWOG-S0517 S0517, NCT00132028

Last Modified: 11/4/2008 First Published: 8/19/2005


10.		Phase II Study of Suberoylanilide Hydroxamic Acid in Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				OSU-04110 6902, NCI-6902, NCT00134043

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute